ImmPro
Accelerator
ImmPro provides top-down proteomics analytical services for biopharmaceutical development using its ProteoSight platform.
Founded
2024ImmPro provides top-down proteomics analytical services for biopharmaceutical development using its ProteoSight platform.
ImmPro's flagship offering is the ProteoSight platform, a proprietary single-particle top-down proteomics system built on Individual Ion Mass Spectrometry (I2MS). The platform enables direct, high-resolution measurement of intact proteins and proteoforms, providing insights that conventional bottom-up methods often miss.
The service portfolio includes gene therapy vector characterization, intact proteoform analysis, disease-specific biomarker assays, and custom biomarker discovery. All services are delivered through a contract research model, with ImmPro acting as an analytical partner to biopharma teams developing complex biologics and gene therapies.
The global proteomics market is expanding as biopharmaceutical developers increasingly seek precise protein characterization to de-risk clinical trials and accelerate timelines. ImmPro is positioned to capture growing demand in gene therapy vector analysis and biomarker discovery, two high-growth segments within the broader life sciences services market.
As regulatory agencies raise expectations for comprehensive biologics characterization, the need for high-resolution, intact protein analysis is expected to rise. ImmPro's platform and services address this need, offering the potential to become a preferred analytical partner for advanced therapeutic development programs.
ImmPro's core advantage lies in its two decades of foundational research and $40 million in funding that underpin the ProteoSight platform, creating a deep intellectual moat in top-down proteomics. The company's ability to measure intact proteoforms at single-particle resolution offers differentiated insights for gene therapy and biologics development.
Additionally, ImmPro's founding team combines world-class scientific expertise with commercial and technical leadership, enabling rapid translation of research into regulatory-ready analytical services. The Northwestern Medicine and Techstars accelerator selection further strengthens its clinical credibility and healthcare network.
